New Delhi: Serum Institute of India (SII), the world's largest vaccine manufacturer, is facing difficulties in importing raw materials from the US. To overcome this problem, the Serum Institute has sought intervention from the central government, so that the smooth manufacture and supply of corona vaccines can continue.
In a letter sent by the Serum Institute to Commerce Secretary Anoop Wadhawan and Foreign Secretary Harsh Vardhan Shringla, it was stated that the US government has implemented the Defense Production Act, due to which the firm is facing problems in importing, including SAIL Culture medicine, raw materials, and some special chemicals are included. The Serum Institute said that the covishield vaccine manufactured by it is being widely used in India and around the world and has been applied to millions of people. Serum Institute said that we are working on several other corona vaccines in technical collaboration with various institutes ie Novavax (US), Codagenix (US), etc., which requires the import of many essential products like raw materials, consumables. it occurs.
SII stated, 'Through the Defense Production Act, the US government has established two priority systems, the Defense Priorities and Allocation System Program (DPAS) and the Health Resource-Priority and Allocation System (HRPAS). There are two main components (preferences and allocation) of HRPAS. Under the priority component, some contracts between government and private entities or between private parties will be given priority over other contracts for the production or distribution of industrial resources required for vaccine production.'
Also Read:
CM Shivraj Singh Chouhan thanks Union Railway Minister Piyush Goyal
Debate in Britain's Parliament on farmers movement, India says 'Discussion on wrong facts'
Corona pace increased in last 24 hours, more than 15000 cases reported